<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397770</url>
  </required_header>
  <id_info>
    <org_study_id>MA-MM-II-002</org_study_id>
    <nct_id>NCT04397770</nct_id>
  </id_info>
  <brief_title>Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma</brief_title>
  <official_title>Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma：a Single-center, Exploratory Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a single-center,exploratory clinical trial aimed to evaluate the objective response
      rate (ORR) of Camrelizumab combined with apatinib and Temozolomide as First Line Therapy in
      Advanced Acral Melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Through study uncompletion, an average of 1 year</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Camre+Apa+TMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1210</intervention_name>
    <description>SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody</description>
    <arm_group_label>Camre+Apa+TMZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib mesylate</intervention_name>
    <description>apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).</description>
    <arm_group_label>Camre+Apa+TMZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide Injection</intervention_name>
    <description>Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).</description>
    <arm_group_label>Camre+Apa+TMZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age:18-75 years, male or female.

          2. Histopathologically confirmed recurrence, inoperable resection or metastatic acral
             melanoma (stage III/IV).

          3. Has not received any systematic anti-tumor drug treatment.

          4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

          5. ECOG 0-1.

          6. Adequate organ function.

          7. Life expectancy of greater than 12 weeks.

          8. Patient has given written informed consent.

        Exclusion Criteria:

          1. Patients who have or are currently undergoing additional chemotherapy, radiation
             therapy, targeted therapy or immunotherapy.

          2. Known history of hypersensitivity to macromolecular protein preparation or any
             components of the SHR- 1210 formulation.

          3. Subjects before or at the same time with other malignant tumors (except which has
             cured skin basal cell carcinoma and cervical carcinoma in situ);

          4. Subjects with any active autoimmune disease or history of autoimmune disease

          5. Uncontrolled clinically significant heart disease, including but not limited to the
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial
             infarction within the past 1 year; (4) clinically significant supraventricular
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;

          6. Active infection or an unexplained fever &gt; 38.5°C during screening or before the first
             scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion
             of the investigator);

          7. Received a live vaccine within 4 weeks of the first dose of study medication.

          8. Pregnancy or breast feeding.

          9. Decision of unsuitableness by principal investigator or physician-in charge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Guo</investigator_full_name>
    <investigator_title>Associate Director of Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

